These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 32828693

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.
    Kawalec P, Moćko P.
    J Comp Eff Res; 2018 Feb; 7(2):101-111. PubMed ID: 29115855
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Short term effectiveness of ustekinumab versus vedolizumab in Crohn's disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis.
    Alamer A, Al Lehaibi LH, Alomar M, Aldhuwayan F, Alshouish S, Al-Ali AY, Almudhry Z, Almulhim A, Althagafi A, Aldosari S, AlAmeel T.
    Saudi J Gastroenterol; 2024 Sep 01; 30(5):324-334. PubMed ID: 39157885
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.
    García MJ, Rivero M, Fernández-Clotet A, de Francisco R, Sicilia B, Mesonero F, de Castro ML, Casanova MJ, Bertoletti F, García-Alonso FJ, López-García A, Vicente R, Calvet X, Barreiro-de Acosta M, Ferrer Rosique J, Varela Trastoy P, Nuñez A, Ricart E, Riestra S, Arias García L, Rodríguez M, Arranz L, Pajares R, Mena R, Calafat M, Camo P, Bermejo F, Ponferrada Á, Madrigal RE, Llaó J, Sesé E, Sánchez E, Pineda Mariño JR, González Muñoza C, Carbajo López AY, Julián AB, Villoria Ferrer A, Baston-Rey I, Jara L, Almela P, Codesido L, de la Maza S, Leal C, Caballol B, Pérez-Martínez I, Vinuesa Campo R, Crespo J, Domènech E, Chaparro M, Gisbert JP.
    J Crohns Colitis; 2024 Jan 27; 18(1):65-74. PubMed ID: 37522878
    [Abstract] [Full Text] [Related]

  • 10. Vedolizumab versus ustekinumab in Crohn's disease with prior anti-tumor necrosis factor failure: an updated meta-analysis.
    Milioli NJ, Fernandes MV, Correa TL, Antunes V, Martins OC, Florêncio de Mesquita C, Baraldo S, Furfaro F.
    Eur J Gastroenterol Hepatol; 2024 Sep 01; 36(9):1068-1074. PubMed ID: 38973525
    [Abstract] [Full Text] [Related]

  • 11. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.
    Onali S, Pugliese D, Caprioli FA, Orlando A, Biancone L, Nardone OM, Imperatore N, Fiorino G, Cappello M, Viola A, Principi MB, Bezzio C, Aratari A, Carparelli S, Mazzuoli S, Manguso F, Grossi L, Bodini G, Ribaldone D, Mocci G, Miranda A, Minerba L, Favale A, Grova M, Scucchi L, Segato S, Fries W, Castiglione F, Armuzzi A, Fantini MC, IG-IBD.
    Am J Gastroenterol; 2022 Aug 01; 117(8):1279-1287. PubMed ID: 35467558
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S.
    Gastroenterology; 2014 Sep 01; 147(3):618-627.e3. PubMed ID: 24859203
    [Abstract] [Full Text] [Related]

  • 15. Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease.
    Alric H, Amiot A, Kirchgesner J, Tréton X, Allez M, Bouhnik Y, Beaugerie L, Carbonnel F, Meyer A.
    Inflamm Bowel Dis; 2022 Feb 01; 28(2):218-225. PubMed ID: 33847351
    [Abstract] [Full Text] [Related]

  • 16. Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection.
    Shah RS, Bachour S, Jia X, Holubar SD, Hull TL, Achkar JP, Philpott J, Qazi T, Rieder F, Cohen BL, Regueiro MD, Lightner AL, Click BH.
    J Crohns Colitis; 2021 Jul 05; 15(7):1142-1151. PubMed ID: 33388775
    [Abstract] [Full Text] [Related]

  • 17. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
    Holko P, Kawalec P, Pilc A.
    Pharmacoeconomics; 2018 Jul 05; 36(7):853-865. PubMed ID: 29667146
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.
    Vu M, Ghosh S, Umashankar K, Weber L, Landis C, Candela N, Chastek B.
    BMC Gastroenterol; 2023 Mar 25; 23(1):87. PubMed ID: 36966279
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Crohn's Disease Patients Who Failed Anti-tumor Necrosis Factor-α Treatment in Japan: An Observational Study Utilizing Claims Database.
    Shimazaki M, Matsuyama Y, Koide D.
    Biol Pharm Bull; 2024 Mar 25; 47(2):443-448. PubMed ID: 38369343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.